Business Description
ISIN : US04335A1051
Total Employee Number:
246Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 70.99 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.6 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.6 | |||||
Beneish M-Score | 4.32 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.5 | |||||
3-Year EBITDA Growth Rate | 30.7 | |||||
3-Year EPS without NRI Growth Rate | 40.1 | |||||
3-Year FCF Growth Rate | 9.6 | |||||
3-Year Book Growth Rate | -13.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -59.15 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -39.34 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.78 | |||||
9-Day RSI | 52.03 | |||||
14-Day RSI | 54.43 | |||||
3-1 Month Momentum % | -7.24 | |||||
6-1 Month Momentum % | -38.21 | |||||
12-1 Month Momentum % | 5.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.91 | |||||
Quick Ratio | 7.91 | |||||
Cash Ratio | 6.88 | |||||
Days Sales Outstanding | 17.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.1 | |||||
Shareholder Yield % | -0.13 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -5.72 | |||||
Net Margin % | 2.94 | |||||
EBITDA Margin % | -4.2 | |||||
FCF Margin % | -65.93 | |||||
OCF Margin % | -65.36 | |||||
ROE % | 1.82 | |||||
ROA % | 1.23 | |||||
ROIC % | -16.64 | |||||
3-Year ROIIC % | -90.44 | |||||
ROC (Joel Greenblatt) % | -132.12 | |||||
ROCE % | -2.87 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 92 | |||||
PE Ratio without NRI | 92 | |||||
PEG Ratio | 11.5 | |||||
PS Ratio | 1.96 | |||||
PB Ratio | 1.07 | |||||
Price-to-Tangible-Book | 1.07 | |||||
EV-to-EBIT | -2.3 | |||||
EV-to-Forward-EBIT | 0.12 | |||||
EV-to-EBITDA | -3.13 | |||||
EV-to-Forward-EBITDA | 0.11 | |||||
EV-to-Revenue | 0.13 | |||||
EV-to-Forward-Revenue | 0.15 | |||||
EV-to-FCF | -0.2 | |||||
Price-to-GF-Value | 0.31 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.68 | |||||
Price-to-Graham-Number | 2.09 | |||||
| Price-to-Net-Current-Asset-Value | 1.11 | |||||
| Price-to-Net-Cash | 1.32 | |||||
Earnings Yield (Greenblatt) % | -43.48 | |||||
FCF Yield % | -34.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ARVN
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Arvinas Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 316.7 | ||
| EPS (TTM) ($) | 0.1 | ||
| Beta | 2.5857 | ||
| 3-Year Sharpe Ratio | -0.1 | ||
| 3-Year Sortino Ratio | -0.15 | ||
| Volatility % | 44.79 | ||
| 14-Day RSI | 54.43 | ||
| 14-Day ATR ($) | 0.371031 | ||
| 20-Day SMA ($) | 9.046 | ||
| 12-1 Month Momentum % | 5.67 | ||
| 52-Week Range ($) | 6.97 - 14.51 | ||
| Shares Outstanding (Mil) | 65.39 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arvinas Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arvinas Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-24 08:00 | In 178 days | ||
| Annual report for 2026 | 2027-02-24 | In 177 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 | In 177 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 08:00 | In 67 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 66 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 08:00 | 8.06 (-0.49%) | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 8.06 (-0.49%) | ||
| General meeting for 2026 | 2026-06-24 08:00 | 8.14 (+6.68%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 09:55 | 8.00 (-5.21%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 08:00 | 9.66 (-4.45%) |
Arvinas Inc Frequently Asked Questions
Guru Commentaries on NAS:ARVN
Arvinas (ARVN), a clinical-stage biotech company developing targeted protein degraders, is down more than 90% from its 2021 highs due to investor disappointment with its trials. Pipeline struggles aside, ARVN has over $1 billion in cash and two significant license/collaboration agreements. With Pfizer, ARVN is eligible to receive up to $1.4 billion of payments upon the approval of ARV-471 and then share equally (50/50) in all profits and losses of the drug. With Novartis, ARVN is eligible to receive up to $1 billion upon the approval of ARV-766, with ongoing tiered royalties thereafter. Despite these assets, ARVN’s market capitalization fell to $500 million in March 2025 upon a disappointing readout for ARV-471. This valuation implies that the company will burn its cash, or that its pipeline will turn out to have minimal value. However, I believe it is unlikely that both will occur.
Arvinas (ARVN), a clinical-stage biotech company developing targeted protein degraders, is down more than 90% from its 2021 highs due to investor disappointment with its trials. However, ARVN has over $1 billion in cash and two significant license/collaboration agreements. With Pfizer, ARVN is eligible to receive up to $1.4 billion of payments upon the approval of ARV-471 and then share equally (50/50) in all profits and losses of the drug. With Novartis, ARVN is eligible to receive up to $1 billion upon the approval of ARV-766, with ongoing tiered royalties thereafter. Despite its current valuation, I believe it is unlikely that both its cash will burn and its pipeline will turn out to have minimal value.
Arvinas (ARVN), a clinical-stage biotech company developing targeted protein degraders, is down more than 90% from its 2021 highs due to investor disappointment with its trials. However, ARVN has over $1 billion in cash and two significant license/collaboration agreements. With Pfizer, ARVN is eligible to receive up to $1.4 billion of payments upon the approval of ARV-471 and then share equally (50/50) in all profits and losses of the drug. With Novartis, ARVN is eligible to receive up to $1 billion upon the approval of ARV-766, with ongoing tiered royalties thereafter. Despite its current valuation, I believe it is unlikely that both its cash will burn and its pipeline will turn out to have minimal value.
Arvinas (ARVN), a clinical-stage biotech company developing targeted protein degraders, is down more than 90% from its 2021 highs due to investor disappointment with its trials. However, ARVN has over $1 billion in cash and two significant license/collaboration agreements. With Pfizer, ARVN is eligible to receive up to $1.4 billion of payments upon the approval of ARV-471 and then share equally (50/50) in all profits and losses of the drug. With Novartis, ARVN is eligible to receive up to $1 billion upon the approval of ARV-766, with ongoing tiered royalties thereafter. Despite its current valuation, I believe it is unlikely that both its cash will burn and its pipeline will turn out to have minimal value.
Press Release
Articles on Arvinas Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
